N-(1-adamantylmethyl)propan-2-amine | 72803-60-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(1-adamantylmethyl)propan-2-amine
• CAS: 72803-60-2
• 化学式: C₁₄H₂₅N
• 分子量: 207.359
• InChiKey: PTHWOBPYACRICM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-氰基金刚烷 、 异丙醇 在 tris(triphenylphosphine)ruthenium(II) chloride 、 sodium hydroxide 作用下， 反应 20.0h， 以79%的产率得到N-(1-adamantylmethyl)propan-2-amine
  参考文献：
  名称：

  腈的钌催化转移氢化：还原和随后的 N-单烷基化成仲胺

  摘要：

  由于胺在大宗和精细化工行业中的应用，胺的选择性合成仍然很重要。本文描述了多米诺钌催化的腈转移氢化反应，随后使用醇进行 N-单烷基化反应。使用这种新方法，各种腈以极好的收率还原 N-单烷基化。

  DOI：

  10.1002/ejoc.201300151

文献信息

• Methyladamantyl hydrazines, their pharmaceutically acceptable salts and pharmaceutical compositions containing them
  申请人：Teva Pharmaceutical Industries Limited

  公开号：EP0002065A1

  公开（公告）日：1979-05-30

  The invention provides novel 1- or 2-adamantylmethyl hydrazines of the general formulaA In this formula Ad is 1- or 2-adamantyl, R1 and R2 are the same or different and are each hydrogen or a lower unsubstituted or substituted alkyl group of 1-4 carbon atoms; R, and R4 are the same or different and are each hydrogen, an unsubstituted or substituted radical being a lower alkyl group of 1-4 carbon atoms, a lower alkanoic acid radical of 2-4 carbon atoms or a lower alkyl ester thereof, adamantyl, aryl, aralkyl in which the alkyl moiety has 1-4 carbon atoms or an unsubstituted or substituted heterocyclic radical of aromatic character; or R3 and R4 together with the nitrogen atom to which they are attached form a cyclic radical of non-aromatic character. The invention further provides pharmaceutically acceptable acid addition salts of the above compounds. Several methods of preparation of the new compounds are described. The novel compounds according to the invention possess valuable antifungal (human and plant), antiviral, antiprotozoal and antimicrobial properties.

  本发明提供了一般式A的新型1-或2-金刚烷基甲基肼化合物。在该式中，Ad为1-或2-金刚烷基，R1和R2相同或不同，均为氢原子或1-4个碳原子的低级未取代或取代烷基基团；R3和R4相同或不同，均为氢原子、未取代或取代的低级烷基基团、2-4个碳原子的低级烷基酸基团或其低级烷基酯、金刚烷基、芳基、芳基烷基（其中烷基部分有1-4个碳原子）或芳香性质的未取代或取代的杂环基团；或R3和R4与它们所连接的氮原子一起形成非芳香性质的环状基团。本发明还提供了上述化合物的药学上可接受的酸加成盐。描述了几种制备新化合物的方法。根据本发明，新型化合物具有有价值的抗真菌（人类和植物）、抗病毒、抗原虫和抗微生物性质。
• Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
  申请人：Saksena K. Anil

  公开号：US20070032433A1

  公开（公告）日：2007-02-08

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明揭示了具有HCV蛋白酶抑制活性的新化合物，以及制备这些化合物的方法。在另一种实施方式中，本发明揭示了包含这些化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
• ORGANIC COMPOUNDS AND THEIR USES
  申请人：Brandl Trixi

  公开号：US20120231998A1

  公开（公告）日：2012-09-13

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
• COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160166545A1

  公开（公告）日：2016-06-16

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
• US4202892A
  申请人：——

  公开号：US4202892A

  公开（公告）日：1980-05-13